451459-92-0

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(4-methylpiperazin-1-yl)-5-nitrobenzonitrile is used as a key intermediate in the synthesis of various pharmaceutical compounds for its ability to be incorporated into diverse molecular structures.
Used in Drug Development for Therapeutic Indications:
In the pharmaceutical industry, 2-(4-methylpiperazin-1-yl)-5-nitrobenzonitrile is utilized as a precursor for developing potential drug candidates aimed at treating a variety of conditions, including antitumor, antimicrobial, and antimalarial therapies.
Used in Enzyme and Receptor Inhibition:
2-(4-methylpiperazin-1-yl)-5-nitrobenzonitrile is employed as a selective and potent inhibitor of certain enzymes and receptors, which is valuable for drug discovery and development processes, particularly in identifying new therapeutic agents with specific targets.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 17417-09-3 2-fluoro-5-nitrobenzonitrile 
• 2516-96-3 2-chloro-5-nitrobenzoic acid 
• 16588-15-1 2-chloro-5-nitro-benzamide 
• 16588-02-6 4-chloro-3-cyanonitrobenzene 

Relevant academic research and scientific papers

FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS

The disclosure provides compounds of formula (I), or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.

PROTEIN KINASE C INHIBITORS AND USES THEREOF

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to ph

N-(3,4-disubstituted phenyl) salicylamide derivatives

A compound represented by the following formula (I) or a salt thereof: wherein R1, R2, R3 and R4 represent hydrogen atom, a halogen atom, cyano group, nitro group, a C1-4 alkyl group, a halogenated C

1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.

AMIDE COMPOUNDS AND MEDICINAL USE THEREOF

The present invention relates to a compound of the formula wherein R1 is substituted aryl, heteroaryl and the like, R2 and R3 are hydrogen, alkyl, halogen, hydroxyl group and the like, Q is N, CH and the like, W is hydrogen, alkyl, hydroxycarbonylalkyl and the like, X is halogen, cyano, nitro, amino and the like, X' is hydrogen, halogen, cyano, nitro, and Y is alkyl, hydroxyl group, alkoxy, mercapto and the like and a salt thereof, and a medicine containing the said compound. The compound of the present invention shows a superior inhibitory effect on activated lymphocytes proliferation and is useful as an agent for the prophylaxis or treatment of various autoimmune diseases.